4.1 Article

UK guideline for the use of HIV post-exposure prophylaxis 2021

期刊

HIV MEDICINE
卷 23, 期 5, 页码 494-545

出版社

WILEY
DOI: 10.1111/hiv.13208

关键词

-

资金

  1. Gilead
  2. Janssen
  3. Wellcome [210772/Z/18/Z]
  4. MSD
  5. GSK
  6. Roche
  7. Sob
  8. Wellcome Trust [210772/Z/18/Z] Funding Source: Wellcome Trust

向作者/读者索取更多资源

This article presents the updated guidelines from the British Association for Sexual Health and HIV (BASHH) on post-exposure prophylaxis (PEP) for HIV. The guidelines aim to provide evidence-based guidance on the best practices for providing, monitoring, and supporting PEP for the prevention of HIV transmission. The guidelines cover topics such as when to prescribe PEP, which antiretroviral agents to use, and how to manage PEP.
We present the updated British Association for Sexual Health and HIV (BASHH) guidelines for post-exposure prophylaxis (PEP) to HIV following sexual exposures, occupational exposures and other nonoccupational exposures in the community. This serves as an update to the 2015 BASHH guideline on PEP following sexual exposures and the 2008 Expert Advisory Group on AIDS guidelines on HIV PEP. We aim to provide evidence-based guidance on best clinical practice in the provision, monitoring and support of PEP for the prevention of HIV acquisition following sexual, occupational and other nonoccupational exposures in the community. The guideline covers when to prescribe PEP, what antiretroviral agents to use and how to manage PEP. This includes (i) evidence of PEP efficacy; (ii) evidence relating to individual-level efficacy of antiretroviral therapy to prevent the sexual transmission of HIV; (iii) data on the detectable (transmissible) prevalence of HIV in specific populations; (iv) risk of HIV transmission following different types of sexual and occupational exposure; (v) baseline risk assessment; (vi) drug regimens and dosing schedules; (vii) monitoring PEP; (viii) baseline and follow-up blood-borne virus testing; (ix) the role of PEP within broader HIV prevention strategies, for example, HIV pre-exposure prophylaxis (PrEP). The guideline also covers special scenarios such as PEP in pregnancy, breastfeeding and chronic hepatitis B virus infection, and when PEP should be considered in people using HIV PrEP. The guidelines are aimed at clinical professionals directly involved in PEP provision and other stakeholders in the field. A proforma to assist PEP consultations is included. A public consultation process was undertaken prior to finalizing the recommendations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据